NASDAQ:KROS

Keros Therapeutics Competitors

$60.16
-2.60 (-4.14 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$59.49
Now: $60.16
$62.73
50-Day Range
$54.00
MA: $60.75
$66.64
52-Week Range
$22.00
Now: $60.16
$88.80
Volume161,258 shs
Average Volume121,950 shs
Market Capitalization$1.40 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Keros Therapeutics (NASDAQ:KROS) Vs. ALLK, BPMC, PRGO, SDGR, GLPG, and AVIR

Should you be buying KROS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Keros Therapeutics, including Allakos (ALLK), Blueprint Medicines (BPMC), Perrigo (PRGO), Schrödinger (SDGR), Galapagos (GLPG), and Atea Pharmaceuticals (AVIR).

Keros Therapeutics (NASDAQ:KROS) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Keros Therapeutics and Allakos, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Keros Therapeutics00403.00
Allakos00403.00

Keros Therapeutics presently has a consensus price target of $78.00, indicating a potential upside of 29.65%. Allakos has a consensus price target of $181.50, indicating a potential upside of 72.86%. Given Allakos' higher probable upside, analysts clearly believe Allakos is more favorable than Keros Therapeutics.

Valuation & Earnings

This table compares Keros Therapeutics and Allakos' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Keros TherapeuticsN/AN/AN/AN/AN/A
AllakosN/AN/A$-85,370,000.00($1.89)-55.56

Insider & Institutional Ownership

58.4% of Keros Therapeutics shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 44.8% of Allakos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Keros Therapeutics and Allakos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Keros TherapeuticsN/AN/AN/A
AllakosN/A-29.18%-27.70%

Summary

Allakos beats Keros Therapeutics on 3 of the 5 factors compared between the two stocks.

Keros Therapeutics (NASDAQ:KROS) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Insider & Institutional Ownership

58.4% of Keros Therapeutics shares are held by institutional investors. 3.8% of Blueprint Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Keros Therapeutics and Blueprint Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Keros TherapeuticsN/AN/AN/A
Blueprint Medicines41.08%43.72%33.35%

Analyst Recommendations

This is a summary of current recommendations and price targets for Keros Therapeutics and Blueprint Medicines, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Keros Therapeutics00403.00
Blueprint Medicines06712.64

Keros Therapeutics presently has a consensus price target of $78.00, indicating a potential upside of 29.65%. Blueprint Medicines has a consensus price target of $111.00, indicating a potential upside of 17.88%. Given Keros Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Keros Therapeutics is more favorable than Blueprint Medicines.

Valuation & Earnings

This table compares Keros Therapeutics and Blueprint Medicines' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Keros TherapeuticsN/AN/AN/AN/AN/A
Blueprint Medicines$66.51 million82.05$-347,690,000.00($7.27)-12.95

Keros Therapeutics has higher earnings, but lower revenue than Blueprint Medicines.

Summary

Blueprint Medicines beats Keros Therapeutics on 7 of the 10 factors compared between the two stocks.

Keros Therapeutics (NASDAQ:KROS) and Perrigo (NYSE:PRGO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Insider and Institutional Ownership

58.4% of Keros Therapeutics shares are held by institutional investors. Comparatively, 82.7% of Perrigo shares are held by institutional investors. 0.3% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Keros Therapeutics and Perrigo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Keros TherapeuticsN/AN/AN/A
Perrigo-0.13%9.78%4.92%

Analyst Ratings

This is a summary of current ratings and target prices for Keros Therapeutics and Perrigo, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Keros Therapeutics00403.00
Perrigo04102.20

Keros Therapeutics currently has a consensus price target of $78.00, indicating a potential upside of 29.65%. Perrigo has a consensus price target of $52.00, indicating a potential upside of 28.30%. Given Keros Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Keros Therapeutics is more favorable than Perrigo.

Valuation and Earnings

This table compares Keros Therapeutics and Perrigo's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Keros TherapeuticsN/AN/AN/AN/AN/A
Perrigo$4.84 billion1.12$146.10 million$4.0310.06

Perrigo has higher revenue and earnings than Keros Therapeutics.

Summary

Perrigo beats Keros Therapeutics on 5 of the 9 factors compared between the two stocks.

Keros Therapeutics (NASDAQ:KROS) and Schrödinger (NASDAQ:SDGR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Insider and Institutional Ownership

58.4% of Keros Therapeutics shares are held by institutional investors. Comparatively, 41.3% of Schrödinger shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Keros Therapeutics and Schrödinger's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Keros TherapeuticsN/AN/AN/A
Schrödinger-19.92%-7.25%-5.33%

Analyst Ratings

This is a summary of current ratings and target prices for Keros Therapeutics and Schrödinger, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Keros Therapeutics00403.00
Schrödinger01302.75

Keros Therapeutics currently has a consensus price target of $78.00, indicating a potential upside of 29.65%. Schrödinger has a consensus price target of $85.50, indicating a potential upside of 15.70%. Given Keros Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Keros Therapeutics is more favorable than Schrödinger.

Valuation and Earnings

This table compares Keros Therapeutics and Schrödinger's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Keros TherapeuticsN/AN/AN/AN/AN/A
Schrödinger$85.54 million60.48$-24,570,000.00N/AN/A

Keros Therapeutics has higher earnings, but lower revenue than Schrödinger.

Summary

Keros Therapeutics beats Schrödinger on 7 of the 8 factors compared between the two stocks.

Keros Therapeutics (NASDAQ:KROS) and Galapagos (NASDAQ:GLPG) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.

Profitability

This table compares Keros Therapeutics and Galapagos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Keros TherapeuticsN/AN/AN/A
Galapagos-70.67%-11.78%-5.58%

Insider & Institutional Ownership

58.4% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 11.2% of Galapagos shares are owned by institutional investors. 2.9% of Galapagos shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and price targets for Keros Therapeutics and Galapagos, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Keros Therapeutics00403.00
Galapagos211402.12

Keros Therapeutics currently has a consensus price target of $78.00, suggesting a potential upside of 29.65%. Galapagos has a consensus price target of $143.7273, suggesting a potential upside of 84.72%. Given Galapagos' higher probable upside, analysts plainly believe Galapagos is more favorable than Keros Therapeutics.

Earnings & Valuation

This table compares Keros Therapeutics and Galapagos' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Keros TherapeuticsN/AN/AN/AN/AN/A
Galapagos$1.00 billion5.08$167.83 million$5.4614.25

Galapagos has higher revenue and earnings than Keros Therapeutics.

Summary

Keros Therapeutics beats Galapagos on 5 of the 8 factors compared between the two stocks.

Atea Pharmaceuticals (NASDAQ:AVIR) and Keros Therapeutics (NASDAQ:KROS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Profitability

This table compares Atea Pharmaceuticals and Keros Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atea PharmaceuticalsN/AN/AN/A
Keros TherapeuticsN/AN/AN/A

Valuation and Earnings

This table compares Atea Pharmaceuticals and Keros Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atea PharmaceuticalsN/AN/AN/AN/AN/A
Keros TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Atea Pharmaceuticals and Keros Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atea Pharmaceuticals00403.00
Keros Therapeutics00403.00

Atea Pharmaceuticals presently has a consensus target price of $69.3333, suggesting a potential upside of 22.69%. Keros Therapeutics has a consensus target price of $78.00, suggesting a potential upside of 29.65%. Given Keros Therapeutics' higher possible upside, analysts clearly believe Keros Therapeutics is more favorable than Atea Pharmaceuticals.

Insider & Institutional Ownership

58.4% of Keros Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Keros Therapeutics beats Atea Pharmaceuticals on 2 of the 2 factors compared between the two stocks.


Keros Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Allakos logo
ALLK
Allakos
1.7$105.00-2.9%$5.58 billionN/A-38.32Insider Selling
Gap Down
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$94.16-0.1%$5.46 billion$66.51 million17.37
Perrigo logo
PRGO
Perrigo
2.5$40.53-0.8%$5.41 billion$4.84 billion-675.39Analyst Report
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.5$73.90-4.1%$5.17 billion$85.54 million0.00Insider Selling
Gap Down
Galapagos logo
GLPG
Galapagos
1.3$77.81-0.1%$5.10 billion$1.00 billion-11.79
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
1.8$56.51-0.5%$4.68 billionN/A0.00Analyst Report
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.61-0.7%$4.47 billion$6.87 million-7.40Analyst Report
Analyst Revision
News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$69.39-2.2%$4.31 billionN/A-5.66Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.24-2.3%$4.26 billion$204.89 million-36.55News Coverage
Gap Up
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35-1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29-0.3%$4.00 billion$806.43 million-9.39
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$78.95-3.9%$3.87 billionN/A-22.49Analyst Report
Gap Down
LEGN
Legend Biotech
1.2$28.45-6.5%$3.76 billion$64.39 million0.00Gap Down
I-Mab logo
IMAB
I-Mab
1.4$51.65-2.3%$3.72 billion$4.31 million-1.79Gap Down
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.77-0.3%$3.67 billion$117.91 million-10.70News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41-0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63-3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.60-1.4%$3.35 billion$306.98 million-6.81
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.56-0.0%$3.34 billionN/A-5.60News Coverage
Insmed logo
INSM
Insmed
1.2$31.70-2.0%$3.27 billion$136.47 million-12.19Analyst Upgrade
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.39-1.4%$3.26 billion$339.08 million-11.85Analyst Downgrade
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.42-7.3%$3.20 billion$26.52 million-7.79Unusual Options Activity
Gap Down
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.91-0.9%$3.16 billionN/A-58.16News Coverage
Arvinas logo
ARVN
Arvinas
1.5$63.49-1.5%$3.10 billion$42.98 million-24.80Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.02-0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25-0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.36-0.8%$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84-4.9%$2.92 billion$260.98 million-380.67Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83-0.2%$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68-1.0%$2.66 billion$306.49 million25.48Insider Selling
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69-0.6%$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77-13.2%$2.56 billionN/A0.00Analyst Report
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77-1.1%$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81-1.4%$2.52 billion$25 million-8.76Insider Selling
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41-8.7%$2.43 billionN/A-21.65News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.29-3.1%$2.38 billion$33.94 million-90.16Insider Selling
News Coverage
Gap Down
Xencor logo
XNCR
Xencor
1.2$40.47-2.9%$2.35 billion$156.70 million-28.91News Coverage
Gap Down
Amarin logo
AMRN
Amarin
1.6$5.93-1.2%$2.33 billion$429.76 million-118.58
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30-1.3%$2.22 billion$15 million-16.39
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.75-0.5%$2.18 billion$963.01 million13.59Analyst Upgrade
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49-16.4%$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09-1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99-2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43-3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35-3.0%$1.93 billion$16.98 million-38.04Insider Selling
Gap Down
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.